|
TSPAN17 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.11022302462516E-15 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.55351295663786E-15 |
| Normal-vs-Stage2 |
1.8453999994783E-07 |
| Normal-vs-Stage3 |
2.02350003419838E-09 |
| Normal-vs-Stage4 |
2.20869999999485E-05 |
| Stage1-vs-Stage2 |
4.002200E-01 |
| Stage1-vs-Stage3 |
2.950600E-01 |
| Stage1-vs-Stage4 |
1.756800E-01 |
| Stage2-vs-Stage3 |
1.318230E-01 |
| Stage2-vs-Stage4 |
8.537500E-02 |
| Stage3-vs-Stage4 |
5.718600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62536650805123E-12 |
| Normal-vs-AfricanAmerican |
2.19050000005439E-06 |
| Normal-vs-Asian |
4.72229999548546E-08 |
| Caucasian-vs-AfricanAmerican |
2.795600E-01 |
| Caucasian-vs-Asian |
8.360600E-01 |
| AfricanAmerican-vs-Asian |
3.521800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.14299960794074E-10 |
| Normal-vs-Female |
1.62569957495862E-12 |
| Male-vs-Female |
5.993800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.32907051820075E-15 |
| Normal-vs-Age(41-60Yrs) |
1.81820003497535E-10 |
| Normal-vs-Age(61-80Yrs) |
5.76690029063798E-10 |
| Normal-vs-Age(81-100Yrs) |
3.68240000000464E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.559690E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.362000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.460800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.603600E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.507600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.888800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.284640E-01 |
| Classical-VS-Follicular |
9.520500E-02 |
| Classical-VS-Other |
1.371980E-02 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
8.712400E-01 |
| Tall-VS-Other |
7.039900E-02 |
| Tall-VS-Normal |
1.954880E-04 |
| Follicular-VS-Other |
1.732360E-01 |
| Follicular-VS-Normal |
1.89190999999589E-05 |
| Other-VS-Normal |
7.971200E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62858615482264E-12 |
| Normal-vs-N1 |
2.080800E-03 |
| N0-vs-N1 |
2.177800E-02 |
|
|
